Circulating Cell-Free DNA as a Prognostic Biomarker in Resectable Ampullary Cancer
Circulating cell-free DNA (cfDNA) in ampullary cancer patients was measured to clarify the correlation between cfDNA and clinicopathological factors and the impact of cfDNA on survival outcomes. Patients with ampullary cancer undergoing pancreaticoduodenectomy were included. Correlations between cfD...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/10/2313 |
| _version_ | 1797534455841161216 |
|---|---|
| author | Bor-Uei Shyr Bor-Shiuan Shyr Shih-Chin Chen Shih-Ching Chang Yi-Ming Shyr Shin-E Wang |
| author_facet | Bor-Uei Shyr Bor-Shiuan Shyr Shih-Chin Chen Shih-Ching Chang Yi-Ming Shyr Shin-E Wang |
| author_sort | Bor-Uei Shyr |
| collection | DOAJ |
| description | Circulating cell-free DNA (cfDNA) in ampullary cancer patients was measured to clarify the correlation between cfDNA and clinicopathological factors and the impact of cfDNA on survival outcomes. Patients with ampullary cancer undergoing pancreaticoduodenectomy were included. Correlations between cfDNA and clinicopathological and prognostic factors were determined. The cfDNA levels in patients ranged from 1282 to 21,674 copies/mL, with a median of 6687 copies/mL. The cfDNA level was significantly higher in patients with lymph node involvement, lymphovascular invasion, abnormal serum carcinoembryonic antigen (CEA) level, and stage II and III cancer. Poor prognostic factors for ampullary cancer included high cfDNA > 6687 copies/mL, lymph node involvement, abnormal serum CEA > 5 ng/mL, and advanced stage II and III cancer. The 1- and 5-year survival rates were 92.0% and 66.5%, respectively, for patients with low cfDNA < 6687 copies/mL and 84.0% and 49.9%, respectively, for patients with high cfDNA > 6687 copies/mL (<i>p</i> < 0.001). After multivariate analysis, only the cfDNA level and stage were independent prognostic factors of ampullary cancer. Thus, the cfDNA level could act as a surrogate marker of both disease extent and biological aggressiveness of ampullary cancer. Moreover, cfDNA plays a significant role in the prognosis of resectable ampullary cancer. |
| first_indexed | 2024-03-10T11:30:45Z |
| format | Article |
| id | doaj.art-7f6ca000ff59467fa6c6070a36c0da6c |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T11:30:45Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-7f6ca000ff59467fa6c6070a36c0da6c2023-11-21T19:18:20ZengMDPI AGCancers2072-66942021-05-011310231310.3390/cancers13102313Circulating Cell-Free DNA as a Prognostic Biomarker in Resectable Ampullary CancerBor-Uei Shyr0Bor-Shiuan Shyr1Shih-Chin Chen2Shih-Ching Chang3Yi-Ming Shyr4Shin-E Wang5Department of Surgery, National Yang Ming Chiao Tung University, Taipei 11221, TaiwanDepartment of Surgery, National Yang Ming Chiao Tung University, Taipei 11221, TaiwanDepartment of Surgery, National Yang Ming Chiao Tung University, Taipei 11221, TaiwanDepartment of Surgery, National Yang Ming Chiao Tung University, Taipei 11221, TaiwanDepartment of Surgery, National Yang Ming Chiao Tung University, Taipei 11221, TaiwanDepartment of Surgery, National Yang Ming Chiao Tung University, Taipei 11221, TaiwanCirculating cell-free DNA (cfDNA) in ampullary cancer patients was measured to clarify the correlation between cfDNA and clinicopathological factors and the impact of cfDNA on survival outcomes. Patients with ampullary cancer undergoing pancreaticoduodenectomy were included. Correlations between cfDNA and clinicopathological and prognostic factors were determined. The cfDNA levels in patients ranged from 1282 to 21,674 copies/mL, with a median of 6687 copies/mL. The cfDNA level was significantly higher in patients with lymph node involvement, lymphovascular invasion, abnormal serum carcinoembryonic antigen (CEA) level, and stage II and III cancer. Poor prognostic factors for ampullary cancer included high cfDNA > 6687 copies/mL, lymph node involvement, abnormal serum CEA > 5 ng/mL, and advanced stage II and III cancer. The 1- and 5-year survival rates were 92.0% and 66.5%, respectively, for patients with low cfDNA < 6687 copies/mL and 84.0% and 49.9%, respectively, for patients with high cfDNA > 6687 copies/mL (<i>p</i> < 0.001). After multivariate analysis, only the cfDNA level and stage were independent prognostic factors of ampullary cancer. Thus, the cfDNA level could act as a surrogate marker of both disease extent and biological aggressiveness of ampullary cancer. Moreover, cfDNA plays a significant role in the prognosis of resectable ampullary cancer.https://www.mdpi.com/2072-6694/13/10/2313ampullarycancercfDNApancreaticoduodenectomy |
| spellingShingle | Bor-Uei Shyr Bor-Shiuan Shyr Shih-Chin Chen Shih-Ching Chang Yi-Ming Shyr Shin-E Wang Circulating Cell-Free DNA as a Prognostic Biomarker in Resectable Ampullary Cancer Cancers ampullary cancer cfDNA pancreaticoduodenectomy |
| title | Circulating Cell-Free DNA as a Prognostic Biomarker in Resectable Ampullary Cancer |
| title_full | Circulating Cell-Free DNA as a Prognostic Biomarker in Resectable Ampullary Cancer |
| title_fullStr | Circulating Cell-Free DNA as a Prognostic Biomarker in Resectable Ampullary Cancer |
| title_full_unstemmed | Circulating Cell-Free DNA as a Prognostic Biomarker in Resectable Ampullary Cancer |
| title_short | Circulating Cell-Free DNA as a Prognostic Biomarker in Resectable Ampullary Cancer |
| title_sort | circulating cell free dna as a prognostic biomarker in resectable ampullary cancer |
| topic | ampullary cancer cfDNA pancreaticoduodenectomy |
| url | https://www.mdpi.com/2072-6694/13/10/2313 |
| work_keys_str_mv | AT borueishyr circulatingcellfreednaasaprognosticbiomarkerinresectableampullarycancer AT borshiuanshyr circulatingcellfreednaasaprognosticbiomarkerinresectableampullarycancer AT shihchinchen circulatingcellfreednaasaprognosticbiomarkerinresectableampullarycancer AT shihchingchang circulatingcellfreednaasaprognosticbiomarkerinresectableampullarycancer AT yimingshyr circulatingcellfreednaasaprognosticbiomarkerinresectableampullarycancer AT shinewang circulatingcellfreednaasaprognosticbiomarkerinresectableampullarycancer |